ATNXQ — Athenex Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.13m
- $74.91m
- $102.82m
Athenex Inc : Jumps on EMA positive opinion for skin condition drug
Brief: Athenex Says Klisyri Received Positive CHMP Opinion From EMA
Athenex Inc reports results for the quarter ended in March - Earnings Summary
Brief: Athenex Inc Says Revenue From Product Sales Increased To $20.4 Mln
U.S. STOCKS ON THE MOVE-Peloton, Athenex, Boeing
U.S. STOCKS ON THE MOVE-HollyFrontier, Hayward Holdings, Athenex
U.S. STOCKS ON THE MOVE-Athenex, Tupperware Brands, Chiasma
Athenex Inc to buy Kuur Therapeutics; shares soar
Brief: IP Group Says Kuur Therapeutics Acquired By Athenex Inc
Brief: Athenex To Acquire Kuur Therapeutics To Expand Cell Therapy Development With Off-The-Shelf Engineered Car-Nkt Platform
Athenex Inc expected to post a loss of 40 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Athenex, Satsuma Pharmaceuticals, Viatris
Brief: Athenex Says Q4 Loss Per Share $0.43 Excluding Items
Brief: Athenex Receives FDA Complete Response Letter For Metastatic Breast Cancer Treatment
Athenex: Drops as FDA declines to approve breast cancer treatment application
NASDAQ RESUMED AT 07:35 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
Brief: Athenex Announces U.S. Launch Of Klisyri And Licensing Of Additional Territories For Tirbanibulin
Brief: Athenex Announces New England Journal Of Medicine Publication Of Phase III Data On Klisyri